Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | STK17B | O94768 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496924 | 1.00 | FLT3 (0.74) | FLT3NPC1RAB9AMAPK1TSHR | |
| Hydrochloric Acid SCHEMBL27610018 | 0.98 | FLT3 (0.71) | FLT3NPC1RAB9AMAPK1TSHR | |
| Hydrochloric Acid SCHEMBL30722382 | 0.98 | FLT3 (0.71) | FLT3NPC1RAB9AMAPK1TSHR | |
| Hydrochloric Acid SCHEMBL5981164 | 0.98 | FLT3 (0.71) | FLT3NPC1RAB9AMAPK1TSHR | |
| Formamide SCHEMBL28325998 | 0.93 | FLT3 (0.65) | FLT3NPC1RAB9AMAPK1TSHR | |
| Formic Acid SCHEMBL27846206 | 0.93 | FLT3 (0.65) | FLT3NPC1RAB9AMAPK1TSHR | |
| Trifluoroacetic Acid SCHEMBL27846344 | 0.88 | FLT3 (0.59) | FLT3NPC1RAB9AMAPK1TSHR | |
| Tetrahydrofuran SCHEMBL28833072 | 0.88 | FLT3 (0.59) | FLT3NPC1RAB9AMAPK1TSHR | |
| Isophthalic Acid SCHEMBL27887534 | 0.87 | NPC1 (0.64) | FLT3NPC1RAB9AMAPK1TSHR | |
| SCHEMBL244107 | 0.85 | FLT3 (1.00) | FLT3NPC1RAB9AMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 724 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229045-B1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BROAD INST INC (US) | 2025-11-12 | — | — | EP | claimed |
| EP-3471714-B1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2025-06-11 | — | — | EP | claimed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | claimed |
| EP-4192814-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-07 | — | — | EP | claimed |
| CN-118056825-A | Vilazodone derivative, synthesis method thereof and application thereof in preparation of antitumor drugs | 复旦大学附属肿瘤医院 | 2024-05-21 | — | — | CN | claimed |
| CN-117836306-A | Galactose glycoside derivatives as galectin-3 inhibitors | 株式会社蒂奥姆生物 | 2024-04-05 | — | — | CN | claimed |
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | claimed |
| CN-117612741-A | Novel coronavirus infection metabolic profile, and construction method, device, system and application thereof | 首都医科大学附属北京朝阳医院 | 2024-02-27 | — | — | CN | claimed |
| CN-117286192-B | Use of amide synthetases in the preparation of litaxetil intermediates and/or litaxetil | 欣雅利华生物技术(上海)有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117286192-A | Use of amide synthetases in the preparation of litaxetil intermediates and/or litaxetil | 欣雅利华生物技术(上海)有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-5264452-A | CNS disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-23 | — | — | US | claimed |
| US-5151437-A | Compounds for treatment of central nervous system disorders | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-29 | — | — | US | claimed |
| EP-0301371-B1 | BENZOFURAN CARBOXAMIDES WITH BASIC SUBSTITUENTS, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1990-12-12 | — | — | EP | claimed |
| EP-0147044-B1 | BENZOFURANCARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | ADRIA LABORATORIES INC. (US) | 1990-04-25 | — | — | EP | claimed |
| US-4868195-A | ENZYME INHIBITORS, ANTIALLERGEN, ASTHMA, CARDIOVASCULAR, ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | claimed |
| EP-0147044-A2 | Benzofurancarboxamides, process for their preparation and pharmaceutical preparations containing them | ADRIA LABORATORIES INC. (US) | 1985-07-03 | — | — | EP | claimed |
| EP-0045473-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING A BENZOFURAN-CARBOXAMIDE DERIVATIVE AS THE ACTIVE INGREDIENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-05-02 | — | — | EP | claimed |
| US-4353923-A | MUSCLE RELAXANTS, ANTIINFLAMMATORY, ANALGESIC | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1982-10-12 | — | — | US | claimed |
| EP-0045473-A1 | A pharmaceutical composition containing a benzofuran-carboxamide derivative as the active ingredient | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1982-02-10 | — | — | EP | claimed |
| US-4009184-A | Amino carbonyl derivatives of benzofurans, processes for their production, and pharmaceutical compositions containing the same 2-phenyl-3-[3-dialkylaminopropanoyl]benzofuran compounds | KALI-CHEMIE AKTIENGESELLSCHAFT (DT) | 1977-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | FLT3 3412/4885NPC1 3276/4885RAB9A 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.